• In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net loss of US$19.78 million, and raised its 2026 net sales guidance to a range of US$620 million to US$635 million.
• At the same time, Glaukos highlighted a broadened ophthalmic portfolio and long-term growth plan, even as insider share sales and continued losses underline ongoing execution and commercialization risks.
• We’ll now explore how the raised 2026 sales guidance reshapes Glaukos’s investment narrative and the outlook implied by current analyst assumptions.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe its growing glaucoma and corneal therapy portfolio can eventually support a profitable, larger-scale ophthalmic business. The raised 2026 sales guidance modestly reinforces that thesis, but the most important near term catalyst still sits with successful commercialization of iDose and Epioxa. The biggest risk remains that continued net losses and high investment needs leave little margin for error if product uptake or reimbursement traction comes in below expectations.

The recent CMS decision to assign a permanent J code for Epioxa, effective July 1, 2026, looks especially relevant here. It directly connects to the updated 2026 sales guidance by potentially easing reimbursement and billing frictions for a key corneal therapy launch. For investors watching Glaukos’s transition from legacy MIGS devices toward a broader ophthalmic platform, Epioxa’s adoption arc now sits alongside iDose as a central test of the growth story.

Yet against this stronger revenue outlook, investors should be aware that reimbursement shifts and high spend could still constrain Glaukos if...

Glaukos’ narrative projects $1.1 billion revenue and $114.2 million earnings by 2029.

Uncover how Glaukos' forecasts yield a $151.08 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a much tougher view than consensus, even before this guidance change, assuming about US$858 million of revenue and only US$55 million of earnings by 2029, so if you are weighing today’s stronger sales outlook against the risk that Epioxa or iDose adoption disappoints, it is worth comparing how your expectations line up with these more cautious scenarios.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 11% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.